


***N*-(4-Methyl-3-phenyl-2,3-dihydro-1,3-thiazol-2-ylidene)benzamide****Aamer Saeed<sup>a\*</sup> and Michael Bolte<sup>b</sup>**<sup>a</sup>Department of Chemistry, Quaid-i-Azam University, Islamabad, Pakistan, and <sup>b</sup>Institut für Anorganische Chemie, J. W. Goethe-Universität Frankfurt, Max-von-Laue-Strasse 7, 60438 Frankfurt/Main, Germany

Correspondence e-mail: aamersaeed@yahoo.com

**Key indicators**Single-crystal X-ray study  
*T* = 173 K  
Mean  $\sigma(\text{C}-\text{C}) = 0.003 \text{ \AA}$   
*R* factor = 0.042  
*wR* factor = 0.114  
Data-to-parameter ratio = 15.0For details of how these key indicators were automatically derived from the article, see <http://journals.iucr.org/e>.Geometric parameters of the title compound,  $\text{C}_{18}\text{H}_{16}\text{N}_2\text{OS}$ , are in the normal ranges. The phenyl ring is twisted by  $68.22(7)^\circ$  out of the plane of the heterocycle.Received 20 March 2007  
Accepted 5 April 2007**Comment**2-Imino-1,3-thiazoline derivatives are associated with various pharmacological activities, for instance antimicrobial (Vittoria *et al.*, 1992), anti-inflammatory (Omar & Eshba, 1984), antihistaminic (Chaudhary *et al.*, 1976), antihypertensive (Ragab *et al.*, 1993), hypnotic (Hassan *et al.*, 1998) and anticonvulsant activities (Turan-Zitouni *et al.*, 2002). Thiazolidinone derivatives of rhodanine are reported to have antibacterial, antiviral (Lee & Sim, 2000), pesticidal (Inamori *et al.*, 1998), anti-inflammatory (Habib *et al.*, 1997) and antidiabetic properties (Sing *et al.*, 2001). Thiazolines have been found to exhibit acaricidal, insecticidal and plant-growth regulatory activities (Hoelzel *et al.*, 1988) and have also been used for the identification of human cells with positive myeloperoxidase reactivity (Bonde & Gaikwad, 2004). 2-Phenylimino-1,3-thiazoline-4-acetanilides have shown significant antifungal activity against rice blast *Pyricularia oryzae*, and thus can be used as agrochemical fungicides (Bae *et al.*, 2005). We have already reported the synthesis of 2-arylimino-3-aryl-4-methyl-1,3-thiazolines by base-catalysed cyclization of 1-aryloxy-3-arylthioureas with acetone in the presence of bromine, which represent a new class of iminothiazolines (Saeed & Parvez, 2006).A perspective view of the title compound is shown in Fig. 1. Geometric parameters are in the normal ranges (Allen *et al.*, 1987). The phenyl ring is twisted by  $68.22(7)^\circ$  out of the plane of the heterocycle.**Experimental**

2-(4-Methylbenzoylimino)-3-phenyl-4-methyl-1,3-thiazoline, (I), was prepared as follows. To a stirred solution of 1-(4-methylbenzoyl)-3-

phenylthiourea (0.002 mol) in acetone (20 ml) containing triethylamine (0.3 ml, 0.002 mol) was added dropwise a solution of bromine (0.002 mol) in acetone (10 ml) under nitrogen. After the addition was complete, the solution was stirred at room temperature overnight. The reaction mixture was filtered and concentrated to leave a crude solid. Recrystallization from aqueous ethanol afforded (I) as colourless crystals (yield 78%; m.p. 455 K).  $R_f$  0.14 (hexane–EtOAc 7:3 v/v); IR (KBr,  $\nu$ ,  $\text{cm}^{-1}$ ): 2938, 1673 (CO), 1600 (C=C), 1514, 1572 (C=N), 1265, 1152, 1050, 783, 736, 700;  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ,  $\delta$ , p.p.m.): 2.07 (s, 3H, C5-Me), 2.48 (s, 3H, Ar-Me), 6.45 (s, 1H, C4-H), 7.14 (2H, AAB), 7.24 (2H, AAB), 7.35 (2H, AAB), 7.67 (2H, AAB).

Crystal data

$\text{C}_{18}\text{H}_{16}\text{N}_2\text{OS}$	$Z = 18$
$M_r = 308.39$	Mo $K\alpha$ radiation
Hexagonal, $R\bar{3}$	$\mu = 0.20 \text{ mm}^{-1}$
$a = 18.8437 (14) \text{ \AA}$	$T = 173 (2) \text{ K}$
$c = 23.561 (2) \text{ \AA}$	$0.26 \times 0.24 \times 0.20 \text{ mm}$
$V = 7245.3 (10) \text{ \AA}^3$	

Data collection

Stoe IPDS II two-circle diffractometer	11573 measured reflections
Absorption correction: multi-scan (MULABS; Spek, 2003; Blessing, 1995)	3025 independent reflections
$T_{\min} = 0.939$ , $T_{\max} = 0.950$	2336 reflections with $I > 2\sigma(I)$
	$R_{\text{int}} = 0.044$

Refinement

$R[F^2 > 2\sigma(F^2)] = 0.042$	201 parameters
$wR(F^2) = 0.114$	H-atom parameters constrained
$S = 1.01$	$\Delta\rho_{\max} = 0.50 \text{ e \AA}^{-3}$
3025 reflections	$\Delta\rho_{\min} = -0.26 \text{ e \AA}^{-3}$

H atoms were located in a difference synthesis but refined with fixed individual displacement parameters [ $U_{\text{iso}}(\text{H}) = 1.2U_{\text{eq}}(\text{C})$  or  $1.5U_{\text{eq}}(\text{C}_{\text{methyl}})$ ] using a riding model, with  $\text{C}_{\text{aromatic}}-\text{H} = 0.95 \text{ \AA}$  and  $\text{C}_{\text{methyl}}-\text{H} = 0.98 \text{ \AA}$ .

Data collection: X-AREA (Stoe & Cie, 2001); cell refinement: X-AREA; data reduction: X-AREA; program(s) used to solve structure: SHELXS97 (Sheldrick, 1997); program(s) used to refine structure: SHELXL97 (Sheldrick, 1997); molecular graphics: PLATON (Spek, 2003); software used to prepare material for publication: SHELXL97.

References

Allen, F. H., Kennard, O., Watson, D. G., Brammer, L., Orpen, A. G. & Taylor, R. (1987). *J. Chem. Soc. Perkin Trans. 2* pp. S1–19.  
 Bae, S., Hahn, H.-G. & Nam, K. D. (2005). *J. Comb. Chem.* **7**, 7–12.




Figure 1 The molecular structure of compound (I), with displacement ellipsoids drawn at the 50% probability level.

Blessing, R. H. (1995). *Acta Cryst.* **A51**, 33–38.  
 Bonde, C. G. & Gaikwad, N. J. (2004). *Bioorg. Med. Chem.* **12**, 2151–2156.  
 Chaudhary, M., Parmar, S. S., Chaudhari, S. K. & Ramasastry, B. V. (1976). *J. Pharm. Sci.* **65**, 443–446.  
 Habib, N. S., Rida, S. M., Badawey, E. A. M., Fahmy, H. T. Y. & Ghazlan, H. (1997). *Eur. J. Med. Chem.* **32**, 759–762.  
 Hassan, H. Y., El-Koussi, N. A. & Farghaly, Z. S. (1998). *Chem. Pharm. Bull.* **46**, 863–865.  
 Hoelzel, H., Creuzburg, D., Stohr, P., Dehne, H., Teller, J., Kranz, L., Luthardt, H., Roethling, T. & Kaestner, A. (1988). German Patent DD 258 168.  
 Inamori, I., Okamoto, Y., Takegawa, Y., Tsujibo, H., Sakagami, Y., Kumeda, Y., Shibata, M. & Numata, K. (1998). *Biosci. Biotechnol. Biochem.* **62**, 1025–1028.  
 Lee, C. L. & Sim, M. M. (2000). *Tetrahedron Lett.* **41**, 5729–5732.  
 Omar, A. M. & Eshba, N. H. (1984). *J. Pharm. Sci.* **73**, 1166–1168.  
 Ragab, F. A., Hussain, M. M., Hanna, M. M. & Hassan, G. S. (1993). *J. Pharm. Sci.* **82**, 387–390.  
 Saeed, A. & Parvez, M. (2006). *J. Heterocycl. Chem.* **43**, 1027–1030.  
 Sheldrick, G. M. (1997). SHELXS97 and SHELXL97. University of Göttingen, Germany.  
 Sing, T. W., Lee, L. C., Yeo, S. L., Lim, S. P. & Sim, M. M. (2001). *Bioorg. Med. Chem. Lett.* **11**, 91–93.  
 Spek, A. L. (2003). *J. Appl. Cryst.* **36**, 7–13.  
 Stoe & Cie (2001). X-AREA. Stoe & Cie, Darmstadt, Germany.  
 Turan-Zitouni, G., Sivaci, D. M., Kaplancikli, Z. A. & Ozdemir, A. (2002). *Il Farmaco*, **57**, 569–571.  
 Vittoria, D. M., Mazzoni, O., Piscopo, E., Caligmano, A. & Bolognese, A. (1992). *J. Med. Chem.* **35**, 2910–2913.